Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ITCI Intra-Cellular Therapies Inc.

盘后交易 12-24 15:27:01 EST

85.24

+1.24

+1.48%

盘后84.71

-0.53-0.62%

14:50 EST

最高85.78	最低83.46	成交量18.72万
今开83.93	昨收84.00	日振幅2.76%
总市值90.37亿	流通市值88.42亿	总股本1.06亿
成交额1,595万	换手率0.18%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ITCI","market":"US","secType":"STK","nameCN":"Intra-Cellular Therapies Inc.","latestPrice":85.24,"timestamp":1735063199999,"preClose":84,"halted":0,"volume":187194,"hourTrading":{"tag":"盘后","latestPrice":84.71,"preClose":85.24,"latestTime":"14:50 EST","volume":3663,"amount":312200.09073,"timestamp":1735069859744},"delay":0,"floatShares":103735508,"shares":106017103,"eps":-0.857916,"marketStatus":"盘后交易","marketStatusCode":4,"change":1.24,"latestTime":"12-24 15:27:01 EST","open":83.93,"high":85.78,"low":83.46,"amount":15945113.78628,"amplitude":0.027619,"askPrice":95.84,"askSize":100,"bidPrice":82.81,"bidSize":53,"shortable":3,"etf":0,"ttmEps":-0.857916,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1735077600000},"adr":0,"adjPreClose":84,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":84.99,"preClose":84,"latestTime":"09:28 EST","volume":443,"amount":37025.054000000004,"timestamp":1735050480075},"postHourTrading":{"tag":"盘后","latestPrice":84.71,"preClose":85.24,"latestTime":"14:50 EST","volume":3663,"amount":312200.09073,"timestamp":1735069859744},"volumeRatio":0.45955,"impliedVol":0.3352,"impliedVolPercentile":0.2262},"requestUrl":"/m/hq/s/ITCI","defaultTab":"news","newsList":[{"id":"2483580988","title":"Intra-Cellular Therapies Inc.盘中异动 大幅下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483580988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483580988?lang=zh_cn&edition=full","pubTime":"2024-11-16 04:35","pubTimestamp":1731702902,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日04时35分，Intra-Cellular Therapies Inc.股票出现异动，股价急速下挫5.04%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为3.04%。其相关个股中，Sunshine Biopharma Inc C/Wts 、Cyclo Therapeutics, Inc.、Evotec Se涨幅较大，Sunshine Biopharma Inc.、大自然药业、Akanda Corp.较为活跃，换手率分别为12.80%、8.49%、6.32%，振幅较大的相关个股有Procaps Group, S.A.、大自然药业、Sunshine Biopharma Inc C/Wts ，振幅分别为30.18%、27.45%、27.12%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116043503abc58fe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116043503abc58fe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","LU0012050646.USD","BK4007","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","ITCI"],"gpt_icon":0},{"id":"2481570398","title":"Intra-Cellular公司的精神分裂症药物在后期试验中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481570398?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:09","pubTimestamp":1730808570,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透11月5日 - Intra-Cellular Therapies公司  周二称，其预防精神分裂症患者复发的药物达到了后期试验的主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0889565916.HKD","LU0320765992.SGD","ITCI","LU0109394709.USD"],"gpt_icon":0},{"id":"2480631303","title":"Intra-Cellular Therapies Inc.2024财年第三财季实现净利润-26.32百万美元，同比减少8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480631303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480631303?lang=zh_cn&edition=full","pubTime":"2024-11-04 07:00","pubTimestamp":1730674851,"startTime":"0","endTime":"0","summary":"11月4日，Intra-Cellular Therapies Inc.公布财报，公告显示公司2024财年第三财季净利润为-26.32百万美元，同比减少8.49%；其中营业收入为1.75亿美元，同比增加38.89%，每股基本收益为-0.25美元。从资产负债表来看，Intra-Cellular Therapies Inc.总负债1.80亿美元，其中短期债务4.20百万美元，资产负债比为7.36，流动比率为7.67。机构评级：截至2024年11月4日，当前有15家机构对Intra-Cellular Therapies Inc.目标价做出预测，其中目标均价为100.80美元，其中最低目标价为79.00美元，最高目标价为135.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104070101a2126c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104070101a2126c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ITCI"],"gpt_icon":0},{"id":"2479722217","title":"美国研究综述-全州保险公司、布林克国际公司、梅塔公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479722217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479722217?lang=zh_cn&edition=full","pubTime":"2024-10-31 15:30","pubTimestamp":1730359839,"startTime":"0","endTime":"0","summary":"    路透10月31日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Allstate、Brinker International 和 Meta。要闻 * 全州公司  ：摩根大通将目标价从207美元上调至217美元             * Blackbaud Inc   ：贝雅将其评级从 \"跑赢大盘 \"下调至 \"中性\"。* Meta   ：贝尔德将目标价从605美元上调至630美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFRM","HUBG","ADP","CAT","GEHC","LU2023250504.SGD","BK4130","SKY","COIN","PDD","IE00B19Z4B17.USD","BIDU","ALRS","LU0882574055.USD","ILMN","BIIB","DHI","FND","ECL","BRO","IE00BYQQ9H92.USD","MSTR","CFLT","IE00B19Z6F94.USD","LU2125910336.SGD","ALL","CTSH","SOFI","CRK","RIVN","ALKT","CLX","BIO","CDW","RIOT","LU1059921491.USD","GRAB","EBAY","BMRC","LU0106261372.USD","EAT","BABA","ATI","HTLF","JKHY","ABBV","EQT","CRWD","BLKB","DASH","IRTC","BKNG","HLI","LU1064131342.USD","LU0354030438.USD","NVDA","KHC","ITCI","FSBC","LU0708994859.HKD"],"gpt_icon":1},{"id":"2479780924","title":"Intra-Cellular Therapies Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2479780924","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479780924?lang=zh_cn&edition=full","pubTime":"2024-10-30 23:21","pubTimestamp":1730301699,"startTime":"0","endTime":"0","summary":"   * Intra-Cellular Therapies Inc   报告了截至9月30日的季度调整后每股亏损25美分，与去年同期持平。华尔街预期为每股-33美分至-9美分。* 营收同比增长 39%，达到 1.7538 亿美元；分析师预期为 1.7235 亿美元。* Intra-Cellular Therapies Inc公布的本季度每股收益为亏损25美分。* 该公司当季亏损 2632 万美元。* Intra-Cellular Therapies Inc的股价本季度上涨了4.9%，今年迄今为止上涨了7.2%。华尔街对 Intra-Cellular Therapies Inc 的 12 个月目标价中位数为 95.00 美元。本摘要由 LSEG 10 月 30 日 03:21 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Intra-Cellular Therapies Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4007","ITCI","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1100771231","title":"异动解读 | 神经药品潜力巨大 ITCI大涨13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100771231","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100771231?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:18","pubTimestamp":1730297934,"startTime":"0","endTime":"0","summary":"北京时间10月30日上午,神经精神药物开发商Intra-Cellular Therapies公司盘中大涨13%,股价一度突破80美元大关,引发市场广泛关注。ITCI正在III期临床试验中研究一种治疗老年痴呆症的新型口服药物,前期结果令人振奋。此外,ITCI的老年痴呆症新药还获得了美国FDA的\"突破性疗法\"认定,有望加快审批进程。因此ITCI的创新疗法无论在医疗水平还是商业潜力上都备受市场热捧,这可能是推动股价大涨的主因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ITCI"],"gpt_icon":0},{"id":"2479786118","title":"Intra-Cellular Therapies Inc.盘中异动 早盘股价大涨5.12%报80.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479786118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479786118?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295119,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，Intra-Cellular Therapies Inc.股票出现异动，股价大幅拉升5.12%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为5.36%。其相关个股中，神经分泌生物科学、Flora Growth Corp.、Intra-Cellular Therapies Inc.涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Flora Growth Corp.、Sunshine Biopharma Inc.较为活跃，换手率分别为15.94%、14.56%、1.39%，振幅较大的相关个股有Intra-Cellular Therapies Inc.、Flora Growth Corp.、神经分泌生物科学，振幅分别为5.11%、4.66%、4.55%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021315998e3f65e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021315998e3f65e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0109394709.USD","ITCI","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2460924967","title":"Intra-Cellular Therapies Inc.2024财年第二财季实现净利润-16.22百万美元，同比增加62.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460924967","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460924967?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824007,"startTime":"0","endTime":"0","summary":"8月17日，Intra-Cellular Therapies Inc.公布财报，公告显示公司2024财年第二财季净利润为-16.22百万美元，同比增加62.09%；其中营业收入为1.61亿美元，同比增加45.05%，每股基本收益为-0.16美元。从资产负债表来看，Intra-Cellular Therapies Inc.总负债1.76亿美元，其中短期债务4.17百万美元，资产负债比为7.51，流动比率为7.81。机构评级：截至2024年8月17日，当前有15家机构对Intra-Cellular Therapies Inc.目标价做出预测，其中目标均价为94.40美元，其中最低目标价为68.00美元，最高目标价为130.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000024959f2819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000024959f2819&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ITCI"],"gpt_icon":0},{"id":"1195467692","title":"异动解读 | Intra-Cellular Therapies Inc.股价大跌6.77% 财报数据疲软拖累","url":"https://stock-news.laohu8.com/highlight/detail?id=1195467692","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195467692?lang=zh_cn&edition=full","pubTime":"2024-08-08 07:08","pubTimestamp":1723072117,"startTime":"0","endTime":"0","summary":"北京时间2024年8月7日,制药公司Intra-Cellular Therapies Inc.(ITCI)股价盘中大跌6.77%,引发市场广泛关注。\n\n公司最新财报数据显示,2024年第二季度实现营业收入1.45亿美元,同比增长45.7%;但净利润为亏损1525万美元,每股亏损0.16美元。公司毛利率为93.1%,市盈率为-64.45倍。\n\n分析师对该公司未来业绩预期也有所下调。根据FactSet最新调查,分析师预计Intra-Cellular Therapies Inc.2024年每股亏损0.63美元,较之前预期的0.5美元有所下调;2025年和2026年每股收益预期也有所下调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI"],"gpt_icon":0},{"id":"2457184796","title":"细胞内治疗公司（Intra-Cellular Therapies Inc）公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2457184796","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457184796?lang=zh_cn&edition=full","pubTime":"2024-08-07 22:23","pubTimestamp":1723040582,"startTime":"0","endTime":"0","summary":"   * Intra-Cellular Therapies Inc   报告了截至6月底的季度调整后每股亏损16美分，高于去年同期的每股-45美分。15 位分析师对该季度的平均预期是每股亏损 19 美分。华尔街预期为每股-27美分至-10美分。* 营收同比增长 45.7%，达到 1.6139 亿美元；分析师预期为 1.5788 亿美元。* Intra-Cellular Therapies Inc公布的本季度每股收益为亏损16美分。* Intra-Cellular Therapies Inc的股价本季度上涨了14.1%，今年迄今为止上涨了9.1%。华尔街对 Intra-Cellular Therapies Inc 的 12 个月目标价中位数为 92.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"细胞内治疗公司（Intra-Cellular Therapies Inc）公布截至 6 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI","LU0109394709.USD","BK4007","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2457841719","title":"Intra-Cellular Therapies Inc.盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457841719","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457841719?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:40","pubTimestamp":1723038034,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时40分，Intra-Cellular Therapies Inc.股票出现异动，股价大幅下挫5.33%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为1.17%。其相关个股中，Petiq, Inc.、Supernus Pharmaceuticals, Inc.、Aquestive Therapeutics, Inc.涨幅较大，Petiq, Inc.、苏轩堂、Emergent Biosolutions, Inc.较为活跃，换手率分别为5.54%、3.15%、1.81%，振幅较大的相关个股有Supernus Pharmaceuticals, Inc.、脑再生科技、德纳维制药，振幅分别为14.10%、13.42%、11.14%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214034af96690c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214034af96690c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","ITCI","BK4007"],"gpt_icon":0},{"id":"2457770708","title":"Intra-Cellular Therapies Inc    预计每股亏损 19 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457770708","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457770708?lang=zh_cn&edition=full","pubTime":"2024-08-06 00:09","pubTimestamp":1722874182,"startTime":"0","endTime":"0","summary":"   * Intra-Cellular Therapies Inc     8月7日公布的截至2024年6月30日的财报显示，该公司的季度收入预计将有所增长。* 根据LSEG的数据，14位分析师的平均预期显示，这家总部位于纽约的公司的营收预计将从去年同期的1.1079亿美元增至1.5788亿美元，增幅为42.5%。* LSEG分析师对Intra-Cellular Therapies Inc的平均预期是每股亏损19美分。* 华尔街对 Intra-Cellular Therapies Inc 的 12 个月目标价中位数为 92.00 美元，高于上一交易日 77.30 美元的收盘价。8月5日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Intra-Cellular Therapies Inc    预计每股亏损 19 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI"],"gpt_icon":0},{"id":"2454029648","title":"Intra-Cellular Therapies Inc.盘中异动 下午盘大幅拉升5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454029648","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454029648?lang=zh_cn&edition=full","pubTime":"2024-07-26 01:06","pubTimestamp":1721927161,"startTime":"0","endTime":"0","summary":"北京时间2024年07月26日01时06分，Intra-Cellular Therapies Inc.股票出现异动，股价急速上涨5.09%。截至发稿，该股报81.21美元/股，成交量57.5996万股，换手率0.55%，振幅5.06%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为1.71%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726010601af942323&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726010601af942323&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4007","LU0109394709.USD","ITCI"],"gpt_icon":0},{"id":"2453751702","title":"Needham：维持Intra-Cellular Therapies(ITCI.US)评级，由买入调整至买入评级, 目标价由94.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453751702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453751702?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:28","pubTimestamp":1721640526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","ITCI"],"gpt_icon":0},{"id":"2446262848","title":"瑞银：下调Intra-Cellular Therapies(ITCI.US)评级，由买入调整至中性评级, 目标价由85.00美元调整至83.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446262848","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446262848?lang=zh_cn&edition=full","pubTime":"2024-06-26 00:15","pubTimestamp":1719332117,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4007","ITCI","LU0889565916.HKD"],"gpt_icon":0},{"id":"2446441218","title":"加拿大皇家银行：重申Intra-Cellular Therapies(ITCI.US)评级，由优于大市调整至优于大市评级, 目标价由103.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446441218","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446441218?lang=zh_cn&edition=full","pubTime":"2024-06-25 22:08","pubTimestamp":1719324509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ITCI","LU0889565916.HKD","BK4007","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2445575584","title":"瑞穗银行：维持Intra-Cellular Therapies(ITCI.US)评级，由买入调整至买入评级, 目标价由96.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445575584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445575584?lang=zh_cn&edition=full","pubTime":"2024-06-21 19:30","pubTimestamp":1718969410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0109394709.USD","LU0320765992.SGD","ITCI","161121","LU0889565916.HKD"],"gpt_icon":0},{"id":"2445368782","title":"美国研究综述-芝加哥商品交易所集团、英格索兰公司、温尼巴戈工业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2445368782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445368782?lang=zh_cn&edition=full","pubTime":"2024-06-21 15:33","pubTimestamp":1718955232,"startTime":"0","endTime":"0","summary":"要闻 * 芝加哥商业交易所集团  ：摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。* 英格索兰公司   ：杰富瑞恢复对该公司的评级，买入；目标价110美元  * 耐克公司  ：奥本海默将其评级从 \"跑赢大盘 \"上调至 \"跑赢大盘\"。* Sarepta Therapeutics Inc   ：加拿大皇家银行将目标价从142美元上调至182美元              * Winnebago Industries Inc   ：杰富瑞将目标价从65美元下调至60美元  以下是路透周五报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CME","LU2133065610.SGD","LU2125909759.SGD","LU1861217088.USD","LU2125909916.SGD","WGO","LU1023059063.AUD","LU1718418525.SGD","SRPT","OHI","LU1548497426.USD","BK4585","LU1303367103.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LII","LU2098885051.SGD","BK4161","LU0070302665.USD","BK4225","NKE","KR","IR","DRI","LU1861220033.SGD","GPN","MSTR","BK4588","CF","LU2347655156.SGD","BK4595","BK4079","LU2023250843.SGD","VTR","ITCI","JLL","LU2023250504.SGD","JBL","LU1861215975.USD","BK4086","ENPH","GMS","ISRG","LU1861220207.SGD","CRK","LU0889565916.HKD","LU1923622291.USD","IE00B2B36J28.USD","VITL","BK4504"],"gpt_icon":1},{"id":"2444432107","title":"BUZZ-Intra-Cellular公司治疗抑郁症的药物在后期试验中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444432107","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444432107?lang=zh_cn&edition=full","pubTime":"2024-06-18 23:31","pubTimestamp":1718724700,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    6月18日 - ** 制药商Intra-Cellular Therapies   股价最高上涨11.1%，达到近两个月的新高76.50美元。 ** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link) ** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙作为治疗重度抑郁症 的药物** 该药名为Calypta，已 被批准用于治疗精神分裂症和与双相情感障碍类型相关的抑郁发作** 年初至今，股价上涨 6.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI","LU0889565916.HKD","BK4007","LU0320765992.SGD","BUZZ","LU0109394709.USD"],"gpt_icon":0},{"id":"2444043533","title":"Intra-Cellular Therapies Inc.盘中异动 早盘急速拉升10.21%报75.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444043533","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444043533?lang=zh_cn&edition=full","pubTime":"2024-06-18 21:31","pubTimestamp":1718717495,"startTime":"0","endTime":"0","summary":"北京时间2024年06月18日21时31分，Intra-Cellular Therapies Inc.股票出现异动，股价急速上涨10.21%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体涨幅为0.37%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Intra-Cellular Therapies Inc.、Aytu Biopharma, Inc.涨幅较大，Sonoma Pharmaceuticals, Inc.、苏轩堂、Akanda Corp.较为活跃，换手率分别为298.82%、1.14%、0.44%，振幅较大的相关个股有Sonoma Pharmaceuticals, Inc.、Flora Growth Corp.、Fsd Pharma Inc.，振幅分别为14.12%、6.42%、6.19%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406182131369f4aa232&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406182131369f4aa232&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","ITCI","LU0889565916.HKD","LU0320765992.SGD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intracellulartherapies.com","stockEarnings":[{"period":"1week","weight":-0.013},{"period":"1month","weight":-0.0197},{"period":"3month","weight":0.1123},{"period":"6month","weight":0.1816},{"period":"1year","weight":0.194},{"period":"ytd","weight":0.1729}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0012},{"period":"3month","weight":0.0411},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.2557},{"period":"ytd","weight":0.2514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intra-cellular Therapies, Inc.（内细胞疗法公司）于2001年5月22日在美国特拉华州注册成立，并于2002年6月开始运营。公司的创立旨在开发药物用于神经和精神疾病的治疗。 ITI公司是一家生物制药公司，专注于创新和发展临床的小分子药物，来改善针对中枢神经系统内精神障碍缺医少药的医疗条件。公司主导产品， ITI- 007 ，临床发展为治疗精神分裂症一流药物。目前用于治疗精神分裂症的药物也没有完全解决中枢神经系统疾病的一系列症状。这些现有的药物也被他们强大的副作用限制。 ITI- 007是用来治疗很多症状，包括急性和残余精神分裂症，具有改进后的安全性和耐受性。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.059554},{"month":2,"riseRate":0.636364,"avgChangeRate":0.027576},{"month":3,"riseRate":0.454545,"avgChangeRate":0.016799},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.004935},{"month":5,"riseRate":0.545455,"avgChangeRate":0.066827},{"month":6,"riseRate":0.727273,"avgChangeRate":0.058875},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.070967},{"month":8,"riseRate":0.272727,"avgChangeRate":0.02247},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.004794},{"month":10,"riseRate":0.454545,"avgChangeRate":0.032707},{"month":11,"riseRate":0.545455,"avgChangeRate":0.035458},{"month":12,"riseRate":0.636364,"avgChangeRate":0.303383}],"exchange":"NASDAQ","name":"Intra-Cellular Therapies Inc.","nameEN":"Intra-Cellular Therapies"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intra-Cellular Therapies Inc.,ITCI,Intra-Cellular Therapies Inc.股票,Intra-Cellular Therapies Inc.股票老虎,Intra-Cellular Therapies Inc.股票老虎国际,Intra-Cellular Therapies Inc.行情,Intra-Cellular Therapies Inc.股票行情,Intra-Cellular Therapies Inc.股价,Intra-Cellular Therapies Inc.股市,Intra-Cellular Therapies Inc.股票价格,Intra-Cellular Therapies Inc.股票交易,Intra-Cellular Therapies Inc.股票购买,Intra-Cellular Therapies Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}